

EDITED BY TOBY L. SIMON • ERIC A. GEHRIE
JEFFREY McCULLOUGH • JOHN D. ROBACK • EDWARD L. SNYDER

ROSSI'S PRINCIPLES OF TRANSFUSION MEDICINE

SIXTH EDITION



WILEY Blackwell

Table of Contents

[Cover](#)

[Title Page](#)

[Copyright Page](#)

[List of contributors](#)

[Preface](#)

[List of abbreviations](#)

[About the companion website](#)

[SECTION I: Transfusion medicine from ancient times to the current pandemic](#)

[CHAPTER 1: Transfusion in the new millennium](#)

[The first animal transfusion](#)

[The first animal-to-human transfusion](#)

[The beginnings of modern transfusion](#)

[The twentieth century](#)

[Anticoagulants, the blood bank, and component therapy](#)

[Transfusion in the age of technology](#)

[Concern for blood safety](#)

[Current status](#)

[Organization of blood services in the United States](#)

[Organization of blood services outside the United States](#)

[Disclaimer](#)

[Key references](#)

CHAPTER 2: Disasters and the blood community
(including COVID-19)

Background

Organization for emergency operations

Planning for blood and transfusion in disasters

Continuity of operations plans

Regulatory considerations in disasters

Records management

The COVID-19 pandemic and transfusion
medicine

Key references

CHAPTER 3: Responding to regulatory challenges
during public health emergencies

Connection between public health emergencies
and blood transfusion

Approach to pandemic management

Case study of a therapeutic: COVID-19
convalescent plasma

Summary

Key references

SECTION II: Blood donation

CHAPTER 4: Recruitment and screening of donors
and the collection of blood

Donor demographics

Donor recruitment and retention

Recipient-specific blood donation

The collection process for blood components for
transfusion: screening, informed consent,
phlebotomy, collection, and postdonation

Educational materials and informed consent

[Blood collection](#)

[The collection process for source plasma: screening, phlebotomy, choice of product, collection, and testing of source plasma donors](#)

[Key references](#)

[CHAPTER 5: Blood donor testing](#)

[Background](#)

[Safety of the blood supply](#)

[Blood component testing](#)

[ABO typing](#)

[Rh typing](#)

[Red blood cell antibody detection](#)

[ABO antibody titers](#)

[Direct antiglobulin testing](#)

[Testing for transmissible diseases](#)

[Plasma for further manufacture: source plasma](#)

[Donor management](#)

[Product management](#)

[Retrieval of in-date products and recipient notification](#)

[Donor Re-entry](#)

[HIV testing](#)

[HIV antibody testing](#)

[Hepatitis B testing](#)

[Hepatitis C testing](#)

[Human T-cell lymphotropic virus testing](#)

[West Nile virus testing](#)

[Zika virus testing](#)

[Testing for babesiosis](#)

[Syphilis testing](#)

[Chagas' disease testing](#)

[CMV testing](#)

[Additional testing for blood derivatives](#)

[Bacterial testing of platelets](#)

[Other laboratory testing](#)

[Extended blood group antigen typing](#)

[Role of platelet antigen typing](#)

[Role of platelet serology](#)

[Parvovirus B19 and hepatitis A virus testing](#)

[Hemoglobin S testing](#)

[Screening donors for IgA deficiency](#)

[Summary](#)

[Key references](#)

[CHAPTER 6: Acute adverse reactions after blood donation](#)

[Adverse reactions after blood donation](#)

[Acute reactions after blood donation:
immediate symptoms and delayed
complications](#)

[Risk factors associated with reactions after
blood donation](#)

[Preventing syncopal reactions at blood drives](#)

[Phlebotomy-related complications](#)

[Phlebotomy-related nerve injury](#)

[Reactions after automated collection of cellular
blood components](#)

[Citrate reactions and other immediate
complications during apheresis procedures](#)

Procedure-related complications related to donation frequency or multiple component collection

Special considerations: granulocyte collection

Conclusion

Key references

CHAPTER 7: Chronic effects of blood and plasma donation

Introduction

Prevalence of and risk factors for iron depletion in blood donors

Regulatory considerations: Role of the Food and Drug Administration and AABB

Adverse outcomes potentially associated with iron depletion

Potentially vulnerable populations

Potential measures for mitigation of iron depletion

Long-term issues for platelet donors

Long-term issues for source plasma donors

Summary

Key references

CHAPTER 8: Global perspective: ensuring blood and blood product safety and availability through regulation and certification

US perspective on ensuring blood and blood product safety and availability

International perspective on ensuring blood and blood product safety and availability

Regulation of and guidance on blood products in Europe

[Authorization in Europe of plasma derivative and analogous recombinant products](#)

[Activities to promote blood component safety in Europe](#)

[Acknowledgement](#)

[Key references](#)

[SECTION III: Blood groups and pretransfusion testing](#)

[CHAPTER 9: Carbohydrate blood groups](#)

[ABO system](#)

[Lewis blood group](#)

[I blood group](#)

[P blood group system](#)

[Sd^a \(SID\)](#)

[Key references](#)

[CHAPTER 10: Rh and LW blood group antigens](#)

[Summary](#)

[Rh blood group system](#)

[LW blood group system](#)

[Summary](#)

[Key references](#)

[CHAPTER 11: Other protein blood groups](#)

[MNS blood group system \(ISBT 002\)](#)

[Lutheran blood group system \(ISBT 005\)](#)

[Kell and Kx blood group systems \(ISBT 006 and 019\)](#)

[Duffy blood group system \(ISBT 008\)](#)

[Kidd blood group system \(ISBT 009\)](#)

[Diego blood group system \(ISBT 010\)](#)

[Xg blood group system \(ISBT 012\)](#)

[Scianna blood group system \(ISBT 013\)](#)

[Colton and GIL blood group systems \(ISBT 015 and 029\)](#)

[Chido/Rodgers blood group system \(ISBT 017\)](#)

[Gerbich blood group system \(ISBT 020\)](#)

[Knops blood group system \(ISBT 022\)](#)

[Indian blood group system \(ISBT 023\)](#)

[Blood group antigens on glycosylphosphatidylinositol-linked proteins: Cartwright \(ISBT 011\), Dombrock \(ISBT 014\), Cromer \(ISBT 021\), JMH \(ISBT 026\), CD59 \(ISBT 035\), KANNO \(ISBT 037\), and EMM \(ISBT 042\)](#)

[Other minor blood group systems: OK \(ISBT 024\), RAPH \(ISBT 025\), JR \(ISBT 032\), LAN \(ISBT 033\), VEL \(ISBT 034\), AUG \(ISBT 036\), CTL2 \(ISBT 039\), PEL \(ISBT 040\), MAM \(ISBT 041\), and ABCC1 \(ISBT 043\)](#)

[Summary](#)

[Disclaimer](#)

[Key references](#)

[CHAPTER 12: Immunohematology and compatibility testing](#)

[Introduction](#)

[Red cell immunology](#)

[Compatibility testing](#)

[Conclusion](#)

[Disclaimer](#)

[Key references](#)

[SECTION IV: Blood components](#)

[PART I: Red cells](#)

CHAPTER 13: Red blood cell production and kinetics

Introduction

Erythropoiesis

Erythropoietin

Nutritional requirements for erythropoiesis

Summary and outlook

Key references

CHAPTER 14: Red blood cell metabolism and preservation

Introduction

Metabolism

Validation of red blood cell quality and in vivo recovery.

Summary

Key references

PART II: Platelets

CHAPTER 15: Platelet production and kinetics

Platelet production

Platelet kinetics

Summary

Key references

CHAPTER 16: Platelet immunology and alloimmunization

Platelet antigens and alloimmunization

Human leukocyte antigens

Human platelet antigens (HPAs)

Transfusion refractoriness

Platelet refractory evaluation

[Overcoming established alloimmunization](#)

[Summary](#)

[Disclaimer](#)

[Acknowledgements](#)

[Key references](#)

[CHAPTER 17: Preparation, preservation, and storage of platelet concentrates](#)

[Preparation of platelets from whole blood: platelet-rich plasma method](#)

[Preparation of platelets from whole blood: buffy-coat method](#)

[Preparation of platelets from plateletpheresis](#)

[Alternative sources of platelets](#)

[Storage conditions](#)

[Acknowledgments](#)

[Key references](#)

[PART III: White cells](#)

[CHAPTER 18: Neutrophil production and kinetics: neutropenia and neutrophilia](#)

[Introduction](#)

[Normal neutrophil kinetics](#)

[Neutrophilia](#)

[Neutropenia](#)

[Key references](#)

[CHAPTER 19: Granulocyte collection and transfusion](#)

[Collection of granulocytes for transfusion](#)

[Granulocyte transfusion in clinical medicine](#)

[Summary and recommendations for clinical practice](#)

[Key references](#)

[PART IV: Plasma](#)

[CHAPTER 20: Composition of plasma](#)

[Plasma composition](#)

[Factors influencing individual plasma composition](#)

[Fibrinolysis and its inhibition](#)

[Summary](#)

[Disclaimer](#)

[Key references](#)

[CHAPTER 21: Plasma and cryoprecipitate for transfusion](#)

[Plasma for transfusion](#)

[Reversal of warfarin effect](#)

[Therapeutic plasma exchange](#)

[Clinical use of cryoprecipitate](#)

[Conclusions](#)

[Key references](#)

[CHAPTER 22: The purification of plasma proteins for therapeutic use](#)

[Introduction](#)

[Key components of the manufacture of plasma protein therapeutics](#)

[Manufacturing controls and assessment of final product for virus safety](#)

[Manufacturing processes for plasma-derived medicinal products](#)

[Summary and outlook](#)

[Acknowledgments](#)

[Key references](#)

[CHAPTER 23: Immunoglobulin products](#)

[Structure and origin of Ig molecules](#)

[A short history of commercial IgG production](#)

[Current IgG products](#)

[Pharmacokinetics and metabolism of IgG](#)

[Adverse reactions to IVIG and SCIG](#)

[Mechanisms of action of IVIG](#)

[Dosing and scheduling IgG treatment regimens](#)

[IgG in transplantation](#)

[Hyperimmune globulins](#)

[Summary](#)

[Key references](#)

[SECTION V: Apheresis](#)

[CHAPTER 24: Basic principles of apheresis and the collection of blood components by apheresis](#)

[Terminology and definitions](#)

[Basic concepts common to all apheresis procedures](#)

[Anticoagulation](#)

[Blood donor apheresis](#)

[Donor apheresis instrumentation](#)

[Product and procedure requirements](#)

[Apheresis complications](#)

[Summary](#)

[Key references](#)

CHAPTER 25: Therapeutic apheresis: plasma processing

Introduction

Therapeutic plasma exchange (TPE)

Conclusions

Acknowledgments

Key references

CHAPTER 26: Therapeutic phlebotomy and cellular hemapheresis

Therapeutic red cell apheresis

Life- or organ-threatening complications

Protozoan disease

Erythrocytapheresis and therapeutic phlebotomy

Therapeutic platelet apheresis

Therapeutic white cell apheresis

Extracorporeal photopheresis

Conclusion

Disclaimer

Key references

SECTION VI: Blood transfusion

CHAPTER 27: Patient blood management

Introduction

Definitions of PBM

Implementing a PBM program

Evidence-based transfusion guidelines

Physician education and monitoring

Preoperative anemia management

Cell salvage

[Acute normovolemic hemodilution \(ANH\)](#)

[Point-of-care testing](#)

[Use of hemostatic agents](#)

[Limiting phlebotomy blood loss for laboratory testing](#)

[Summary](#)

[Acknowledgments](#)

[Key references](#)

[CHAPTER 28: Clinical and technical aspects of blood administration](#)

[Introduction](#)

[Pretransfusion considerations](#)

[Component issue, release, storage, and transport](#)

[Component modification and preparation](#)

[At the bedside: transfusion administration](#)

[Key references](#)

[CHAPTER 29: Anemia and red blood cell transfusion](#)

[Introduction](#)

[Adaptive mechanisms in anemia](#)

[Microcirculatory effects of anemia and red cell transfusion](#)

[Interaction between pathophysiologic processes and anemia](#)

[Clinical outcomes of anemia and red cell transfusion](#)

[Future](#)

[Summary](#)

[Disclaimer](#)

Key references

CHAPTER 30: Sickle cell disease, thalassemia, and hereditary hemolytic anemias

Introduction

Malaria, hematologic diseases, and blood groups

Structural hemoglobin mutations

Thalassemia

RBC enzymopathies

RBC membrane mutations

Blood groups

Sickle cell disease

Thalassemia

Red cell enzymopathies

Red cell membrane disorders

Transfusion protocols

Transfusion targets and monitoring

Transfusion complications

Key references

CHAPTER 31: Autoimmune hemolytic anemias and paroxysmal nocturnal hemoglobinuria

Autoimmune hemolytic anemias (AIHAs)

Overall classification

Warm autoimmune hemolytic anemia (WAIHA)

Cold autoimmune hemolytic anemia

Paroxysmal nocturnal hemoglobinuria (PNH)

Epidemiology and risk factors

Pathophysiology

Clinical findings

[Treatment](#)

[Special clinical situations](#)

[Children](#)

[Transfusion management](#)

[Prognosis](#)

[Summary](#)

[Key references](#)

[CHAPTER 32: Hemolytic disease of the fetus and newborn](#)

[Background](#)

[Immune-mediated HDFN](#)

[Monitoring and management of sensitized pregnancies](#)

[Conclusion](#)

[Key references](#)

[CHAPTER 33: Obstetric transfusion practice](#)

[Introduction](#)

[Blood loss in pregnancy](#)

[Transfusions in pregnancy](#)

[Fetal transfusions](#)

[Conclusion](#)

[Acknowledgment](#)

[Key references](#)

[CHAPTER 34: Transfusion in infants and children](#)

[Red blood cell transfusion](#)

[Platelet transfusion](#)

[Transfusion reactions in the pediatric population](#)

[Plasma transfusion](#)

[Cryoprecipitate transfusion](#)

[Disclaimer](#)

[Key references](#)

[CHAPTER 35: Thrombocytopenia and platelet transfusion](#)

[Thrombocytopenia](#)

[Platelet transfusion](#)

[Summary](#)

[Disclaimer](#)

[Key references](#)

[CHAPTER 36: Management of immune-mediated thrombocytopenia](#)

[Introduction](#)

[Laboratory tests for the investigation of thrombocytopenia](#)

[Immune-mediated thrombocytopenic syndromes](#)

[Summary](#)

[Acknowledgment](#)

[Key references](#)

[CHAPTER 37: Coagulation concentrates for inherited bleeding disorders](#)

[Introduction](#)

[Hemophilia](#)

[von Willebrand disease](#)

[Other rare congenital clotting protein disorders](#)

[Key references](#)

[CHAPTER 38: Coagulation factor concentrates and pharmacologic therapies for acquired bleeding disorders](#)

[Introduction](#)

[Prothrombin complex concentrate](#)

[Recombinant activated factor VII](#)

[Vitamin K](#)

[Antifibrinolytic agents](#)

[Desmopressin](#)

[Protamine](#)

[Andexanet alfa](#)

[Idarucizumab](#)

[Clinical settings](#)

[Acknowledgment](#)

[Disclaimer](#)

[Key references](#)

[CHAPTER 39: Perioperative transfusion practice](#)

[Background](#)

[Anemia and surgery](#)

[Impact of RBC transfusions on surgical patient outcomes](#)

[The utility of preoperative hemostatic testing](#)

[Management of perioperative anticoagulation and antiplatelet therapies](#)

[Conservative versus liberal transfusion practices](#)

[Blood avoidance techniques](#)

[Topical hemostatic therapies](#)

[Perioperative transfusion guidelines](#)

[The role of plasma transfusion in special circumstances](#)

[The role of platelet transfusion in special circumstances](#)

[Key references](#)

[CHAPTER 40: Transfusion therapy in the care of trauma and burn patients](#)

[The evolution of the approach to blood product resuscitation for severely injured patients](#)

[The epidemiology of physical injury](#)

[Clinical approach to the trauma patient](#)

[Clinical approach to the mass casualty trauma situation](#)

[Initial resuscitation of the burn patient](#)

[Transfusion therapy in the care of the severely burned](#)

[Adjuncts in transfusion therapy for trauma and burn patients](#)

[Summary](#)

[Key references](#)

[CHAPTER 41: Transfusion support for the oncology patient](#)

[Red cell transfusion](#)

[Platelet transfusion](#)

[Plasma and plasma-derived product transfusion](#)

[Granulocyte transfusion](#)

[Adverse reactions to blood transfusion](#)

[Summary](#)

[Acknowledgments](#)

[Key references](#)

[CHAPTER 42: Pathogen-reduced blood components and derivatives](#)

[Introduction](#)

[Overview of pathogen reduction technologies](#)

[Pathogen reduction technologies—mechanisms of action](#)

[Efficacy of pathogen reduction](#)

[Pathogen reduction for noncellular blood components](#)

[In vitro and in vivo quality of pathogen-reduced cellular components](#)

[In vivo studies in healthy human subjects](#)

[Immunological effects of pathogen-reduced blood components](#)

[Safety and toxicity of pathogen-reduced technologies](#)

[Summary](#)

[Key references](#)

[SECTION VII: Adverse sequelae of transfusion](#)

[CHAPTER 43: Hemovigilance: weighing the risks versus benefits of transfusion](#)

[Introduction](#)

[Risk](#)

[Reporting and learning systems in transfusion](#)

[Hemovigilance data analysis, assessment, and reporting](#)

[Key references](#)

[CHAPTER 44: Transfusion-transmitted viral infections \(TTVIs\)](#)

[Introduction](#)

[Hepatitis virus infections \(A, B, C, D, and E\)](#)

[Retroviruses](#)

[Lentivirus diseases](#)

[Flaviviruses](#)

[Alphavirus infection](#)

[Herpesvirus infections](#)

[Parvovirus B19 infections](#)

[Filoviridae](#)

[Pandemic influenza](#)

[Other viruses](#)

[Summary](#)

[Disclaimer](#)

[Acknowledgment](#)

[Key references](#)

[CHAPTER 45: Transfusion transmission of parasites and prions](#)

[Summary](#)

[Babesiosis](#)

[Chagas disease](#)

[Malaria](#)

[Leishmaniasis](#)

[Toxoplasmosis](#)

[Microfilariasis](#)

[Prion diseases](#)

[Molecular mechanisms of prion conversion](#)

[The nature, concentration, and distribution of infectivity in blood and tissues](#)

[Transfusion Transmissibility of variant and sporadic CJD](#)

[Regulatory measures to reduce the risk of transfusion transmission of sCJD and vCJD](#)

[Summary](#)

[Key references](#)

[CHAPTER 46: Bacterial contamination of blood components](#)

[Introduction](#)

[Bacterial contamination of platelets](#)

[Strategies to reduce the risk of post-transfusion sepsis \(Table 46.2\)](#)

[Pathogen reduction](#)

[Bacterial contamination of red blood cells](#)

[Bacterial contamination of plasma, cryoprecipitate, and derivatives](#)

[International comparison](#)

[Conclusion](#)

[Disclaimer](#)

[Conflict of interest](#)

[Key references](#)

[CHAPTER 47: Hemolytic transfusion reactions](#)

[Incidence](#)

[Causes of HTRs](#)

[Pathophysiology](#)

[Role of complement](#)

[Role of macrophages](#)

[Bystander hemolysis](#)

[Reticulocyte suppression/destruction](#)

[Clinical manifestations and diagnosis](#)

[Complications](#)

[Management](#)

[Prevention](#)

[Summary](#)

[Disclaimer](#)

[Acknowledgments](#)

[Key references](#)

[CHAPTER 48: Nonhemolytic transfusion reactions](#)

[Febrile nonhemolytic transfusion reactions](#)

[Allergic reactions](#)

[Anaphylactic and anaphylactoid reactions](#)

[Complications of massive and rapid transfusion](#)

[Toxic reactions resulting from blood
manufacture or processing](#)

[Reactions in special transfusion settings](#)

[Summary](#)

[Disclaimer](#)

[Key references](#)

[CHAPTER 49: Transfusion-related acute lung injury and other respiratory-related transfusion reactions](#)

[TRALI: clinical features](#)

[Pathophysiology](#)

[Diagnosis](#)

[Incidence and epidemiology](#)

[Management and outcome](#)

[Prevention](#)

[Other respiratory-related transfusion reactions](#)

[Transfusion-associated dyspnea \(TAD\)](#)

[Conclusion](#)

[Disclaimer](#)

[Acknowledgement](#)

[Key references](#)

CHAPTER 50: Transfusion-associated graft-versus-host disease

Pathophysiology of TA-GVHD

Incidence of TA-GVHD

Clinical scenarios associated with TA-GVHD

Diagnosis of TA-GVHD

Prevention of TA-GVHD

Treatment of TA-GVHD

Conclusion

Key references

CHAPTER 51: Transfusional iron overload

Introduction

Pathophysiology

Transfusional iron burden

Clinical features

Measurement of iron burden

Management

Summary

Key References

SECTION VIII: Cellular and tissue transplant technologies

CHAPTER 52: Hematopoietic growth factors

Introduction

General principles of hematopoietic growth factors

Erythroid growth factors

Myeloid growth factors

Thrombopoietic growth factors

General conclusions

[Acknowledgments](#)

[Key references](#)

[CHAPTER 53: Hematopoietic stems cells and transplantation](#)

[Stem cells](#)

[Hematopoietic stem cells](#)

[Key references](#)

[CHAPTER 54: HLA antigens, alleles, and antibodies](#)

[Major histocompatibility complex](#)

[Class I and II antigens and their function](#)

[Nomenclature and polymorphism of the HLA system](#)

[Identification of HLA antigens and alleles](#)

[Choice of HLA typing method](#)

[Summary](#)

[Disclaimer](#)

[Acknowledgments](#)

[Key references](#)

[CHAPTER 55: Chimeric antigen receptor T cells and other cellular immunotherapies](#)

[Introduction](#)

[T-cell immunotherapy](#)

[Conclusions](#)

[Key references](#)

[CHAPTER 56: Gene therapy applications to transfusion medicine](#)

[Introduction](#)

[Gene therapy and transfusion medicine](#)

[Gene selection and targeted insertion](#)

[Gene therapy administration](#)

[Vector selection](#)

[Ensuring viral vectors are replication incompetent](#)

[Risks](#)

[Nonviral gene therapy vectors](#)

[Gene editing](#)

[Transfusion-medicine-related gene therapy trials](#)

[Gene therapy and vaccines: a unique frontier of exploration](#)

[Summary](#)

[Disclaimer](#)

[Key references](#)

[CHAPTER 57: Tissue engineering and regenerative medicine](#)

[Lung Tissue Engineering](#)

[Reproductive System Tissue Engineering](#)

[Peripheral Nerve System Tissue Engineering](#)

[Skeletal Muscle Tissue Engineering](#)

[Gastrointestinal Tissue Engineering](#)

[Renal Tissue Engineering](#)

[Bone Tissue Engineering Update](#)

[Vascular Tissue Engineering Update](#)

[Cardiac Tissue Engineering Update](#)

[Cartilage Tissue Engineering Update](#)

[Skin Tissue Engineering Update](#)

[Urology Tissue Engineering Updates—Urethra](#)

[Concluding Remarks](#)

[Key references](#)

[CHAPTER 58: Human tissue allografts: responsibilities in understanding the path from donor to recipient](#)

[Introduction](#)

[General principles of tissue preservation, storage, and clinical use](#)

[Donor-recipient matching: is it necessary?](#)

[Oversight, tracking, and traceability of human tissues](#)

[Conclusion](#)

[Acknowledgments](#)

[Key references](#)

[Index](#)

[End User License Agreement](#)

List of Tables

Chapter 1

[Table 1.1 Increase in the Number of Blood Transfusions at Mount Sinai Hospi...](#)

[Table 1.2 Transfusions in the United States \(in Millions of Units\)...](#)

Chapter 2

[Table 2.1 Resources to Assist in Development and Improvement of Local Plans...](#)

[Table 2.2 Elements Critical for Inclusion in a Continuity of Operations Pla...](#)

Chapter 3

[Table 3.1 Some Established and Potential Transfusion Transmitted Infections...](#)

[Table 3.2 Four Key Aspects of Epidemic and Pandemic Response](#)

Chapter 5

[Table 5.1 Donor Testing Performed in the United States](#)

[Table 5.2 Automated Systems for Red Cell Typing and Antibody Testing of Don...](#)

[Table 5.3 Automated Testing Systems for Infectious Disease of Donated Blood...](#)

[Table 5.4 Sequence of Testing of Donated Blood](#)

[Table 5.5 Donor Management of Reactive Infectious Disease Results](#)

[Table 5.6 In-Date Product Retrieval and Recipient Notification](#)

Chapter 6

[Table 6.1 Adverse Reactions after Allogeneic Whole Blood and Apheresis Dona...](#)

[Table 6.2 Variables Associated with Syncopal Reactions after Blood Donation...](#)

[Table 6.3 Strategies to Reduce Reactions Among Blood Donors](#)

Chapter 7

[Table 7.1 Hemoglobin and Iron Status at Enrollment in REDS-II RISE Study](#)

Chapter 8

[Table 8.1 21 CFR Part 211 cGMP for Finished Pharmaceuticals](#)

[Table 8.2 21 CFR Parts 600-640: Applicable Sections for Blood and Blood Pro...](#)

[Table 8.3 Elements of Current Good Manufacturing Practice](#)

[Table 8.4 Quality Function Responsibilities](#)

[Table 8.5 Reportable Event Criteria](#)

[Table 8.6 Synopsis of Final Rule on Reporting Biological Product Deviations...](#)

Chapter 9

[Table 9.1 Group A Structures in Humans](#)

[Table 9.2 ABO Serology](#)

[Table 9.3 Examples of ABO Alleles](#)

[Table 9.4 Lewis Serology and Genetics](#)

[Table 9.5 GCNT2 Mutations Associated with \$i_{adult}\$ Phenotype](#)

[Table 9.6 GSL Structures Related to Globo, P1, and PX2 Synthesis](#)

[Table 9.7 P Blood Group Serology](#)

Chapter 10

[Table 10.1 Nomenclature and Prevalence of Rh Haplotypes](#)

[Table 10.2 International Society for Blood Transfusion \(ISBT\) Numerical Ter...](#)

Chapter 11

[Table 11.1 Overview of the Protein Blood Group Systems other than Rh, RhAG,...](#)

Chapter 12

[Table 12.1 Characteristics of Blood Group Antibodies](#)

[Table 12.2 Blood Group Antibody, Class, Clinical Significance, and % Antige...](#)

[Table 12.3 Overview of Antiglobulin Tests](#)

[Table 12.4 Pretransfusion Compatibility Testing](#)

[Table 12.5 The Expected Reactions of the Four Common ABO Phenotypes: Result...](#)

[Table 12.6 Methods for Pretransfusion Antibody Detection](#)

[Table 12.7 Results of Antibody Identification Panel with a Serum Containing...](#)

[Table 12.8 DNA-Based Typing for Patient and Donor Testing](#)

Chapter 14

[Table 14.1 Compositions and Properties of Some of the Common Acid Citrate P...](#)

[Table 14.2 Compositions of the Common Licensed First-Generation RBC Additiv...](#)

[Table 14.3 Composition and Properties of Some of the Second-Generation RBC ...](#)

[Table 14.4 Effect of Storage Duration of Characteristics of RBC Concentrate...](#)

Chapter 16

[Table 16.1 Platelet Alloimmunization in Multitransfused Patients Receiving ...](#)

[Table 16.2 Human Platelet Antigens.](#)

[Table 16.3 Calculations Determining Platelet Count Increment in the Evaluat...](#)